Article Text

Correspondence response
Response to H Zeidler's comments on the CONCERTO study
  1. Gerd R Burmester1,
  2. Alan Kivitz2,
  3. Hartmut Kupper3,
  4. Udayasankar Arulmani4,
  5. Stefan Florentinus5,
  6. Sandra L Goss4,
  7. Suchitrita S Rathmann4,
  8. Roy M Fleischmann6
  1. 1Charité—University Medicine Berlin, Berlin, Germany
  2. 2Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA
  3. 3AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
  4. 4AbbVie Inc., North Chicago, Illinois, USA
  5. 5AbbVie, Rungis, France
  6. 6University of Texas Southwestern, Dallas, Texas, USA
  1. Correspondence to Dr Gerd R Burmester, Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin 10117, Germany; gerd.burmester{at}

Statistics from

We thank Dr Zeidler for his interest in our manuscript,1 expressed in his recent letter to the editor.2 While Dr Zeidler raises interesting questions regarding methotrexate (MTX) bioavailability and the differences between oral and subcutaneous formulations of MTX, these are outside the scope of the CONCERTO study. Thus, it is important to reiterate that the objective of the study was to assess the oral dose of (MTX), which when co-administered with the tumour necrosis factor inhibitor, adalimumab (ADA), is required to optimise the benefit:risk profile in patients with early rheumatoid arthritis (RA), who were MTX naive. We agree with Dr Zeidler that this is not the usual course, nor one generally recommended by the European League Against Rheumatism (EULAR), of initiating a biological therapy for the treatment of RA; however, it was critical to assess …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles